Description
VG2025 is an experimental compound being developed for treatment of colorectal cancer with liver metastases. Based on available clinical trial data, it is being tested in combination with AK112 (an anti-PD-1/VEGF bispecific antibody) in a Phase 1 study. The specific drug class and molecular target of VG2025 have not been publicly disclosed in current trial documentation.
Mechanism of Action
The precise molecular mechanism of action for VG2025 remains undisclosed in publicly available clinical trial information. Given its pairing with AK112 in combination therapy for metastatic colorectal cancer, it likely targets a complementary pathway to enhance anti-tumor efficacy.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.